ArticleEuropean journal of nuclear medicine and molecular imaging2020
The
Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 5 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Investigating the significance of SPECT/CT-SUV for monitoringBMC medical imaging · 2025Pooled it
- Bibliometric and scientometric analysis of PSMA-targeted radiotheranostics: knowledge mapping and global standing.Frontiers in oncology · 2024Pooled it
- Joint EANM/SNMMI procedure guideline for the use ofEuropean journal of nuclear medicine and molecular imaging · 2023Guideline
- Pooled it
- Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2020Pooled it
- Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer.Nature reviews. Urology · 2026Review
- Impact of extended [European journal of nuclear medicine and molecular imaging · 2025Article
- Development of a CT-less SPECT Acquisition Protocol for Kidney Dosimetry inMolecular imaging and biology · 2025Article
- Validation of dosimetry programs (Olinda & IDAC) for evaluation of absorbed dose inEJNMMI physics · 2024Article
- Efficacy and safety of rechallenge with [European journal of nuclear medicine and molecular imaging · 2024Article
- A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?EJNMMI physics · 2024Review
- Treatment response assessment in mCRPC: is PSMA-PET/CT going to take the lead?Therapeutic advances in medical oncology · 2024Review
- Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Development of [European journal of nuclear medicine and molecular imaging · 2023Article
- Advances in PET imaging of cancer.Nature reviews. Cancer · 2023Review
- 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art.The oncologist · 2022Review
- Pharmacological Optimization of PSMA-Based Radioligand Therapy.Biomedicines · 2022Review
- Theragnostic Radionuclide Pairs for Prostate Cancer Management:Biomedicines · 2022Review
- Production Review of Accelerator-Based Medical Isotopes.Molecules (Basel, Switzerland) · 2022Review
- Review
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionA new therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) of heavily pre-treated patients lies in
methodsOn the basis of PSMA-targeted
results
conclusionSerial PSA measurements and post-therapy 24 h WB scintigraphy seems to allow a sufficiently accurate follow-up of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.